Hydroxychloroquine/oseltamivir

  • PDF / 170,056 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 11 Downloads / 150 Views

DOWNLOAD

REPORT


1 OS

Various toxicity following off label therapy: case report A 28-year-old man developed prolongation of QT interval, bradycardia, weakness, nausea and diarrhoea following an accidental overdose of off-label hydroxychloroquine for COVID-19 infection. He also received off-label treatment oseltamivir for COVID-19 infection [not all outcomes stated]. The man, who presented with weakness, nausea and diarrhoea, was admitted to the emergency department. One day before presentation, he was diagnosed with COVID-19 infection and prescribed off-label treatment with oral hydroxychloroquine 2 × 200mg and oseltamivir 2 × 75mg for 5 days with home isolation. He accidentally consumed 1600mg of hydroxychloroquine, and after 6 hours, he showed side-effects for which he presented to the emergency department. Abdominal, respiratory and neurological examinations were normal, and the Glasgow Coma Scale score was 15. Investigation showed the following: arterial blood pressure 122/82 mm Hg, pulse 54 beats/min, oxygen saturation 99% and fever 36.5°C. Electrocardiography revealed a QT interval of 510ms and sinus bradycardia. Tests were normal for blood electrolytes, blood count, C-reactive protein and kidney and liver function. Additionally, his blood potassium level was found to be 3.2 mEq/L, and he received a liquid supplement of sodium chloride and potassium chloride. However, his bradycardia and QT interval prolongation persisted. Hydroxychloroquine was discontinued, and the man continued oseltamivir. On day 3, he was discharged from hospital with improved bradycardia and corrected QT intervals. Aksel G, et al. Prolongation of QT interval due to hydroxychloroquine overdose used in COVID-19 treatment. Turkish Journal of Emergency Medicine 20: 149-151, No. 3, 18 803499562 Jul 2020. Available from: URL: http://doi.org/10.4103/2452-2473.290063

0114-9954/20/1820-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 5 Sep 2020 No. 1820

Data Loading...